

Synthesis of Tetrazines from *gem*-Difluoroalkenes under aerobic condition at room temperature


Zheng, Fang^a, Wen-Li Hu^a, De-Yong Liu^a, Chu-Yi Yu^{a,b}, Xiang-Guo Hu*^a

SUPPORTING INFORMATION

1. Reagents and instrumentation.....	2
2. Preparation of 1,1-difluoroalkenes by decarboxylation of sodium chlorodifluoacetate.	3
3. Synthesis of symmetric 3,6-dialkyl-1,2,4,5-tetrazine(3a–3h).....	5
4. Synthesis of asymmetric 3,6-dialkyl-1,2,4,5-tetrazines (5a–5l).....	8
5. Screen of the solvent effect in the conversion of gem-difluoroalkene 1a to fluorohydrazone 2a^a	12
6. NMR spectra of novel compounds and intermediate	13
7. NMR comparison of 1a and fluorohydrazone 2a in CD ₃ CN	33


1. Reagents and instrumentation

All reagents were used as received from commercial sources without further purification or prepared as described in the literature. All solvents were dried over 4Å molecular sieves before use unless otherwise stated. Reactions were stirred using Teflon-coated magnetic stirring bars. Analytical TLC was performed with 0.20 mm silica gel 60F plates with 254 nm fluorescent indicator. TLC plates were visualized by ultraviolet light or by treatment with a spray of Pancaldi reagent { $(\text{NH}_4)_6\text{MoO}_4$, $\text{Ce}(\text{SO}_4)_2$, H_2SO_4 , H_2O } or a solution 0.5% ninhydrin in n-butanol. Chromatographic purification of products was carried out by flash column chromatography on silica gel (230-400 mesh). Melting points were determined using a WRX-4 visual melting point apparatus. Both melting points and boiling points are uncorrected. Infrared spectra were recorded on a IR Affinity-1. NMR spectra were measured in CDCl_3 (with TMS as internal standard) or D_2O or MeOD on a Bruker AV400 (^1H at 400 MHz, ^{13}C at 100 MHz, ^{19}F at 376 MHz) magnetic resonance spectrometer. High-resolution mass spectra (HRMS) were recorded on a SYNAPT G2Si High Definition MS System. Chemical shifts (δ) are reported in ppm, and coupling constants (J) are in Hz. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. The HRMS were measured under ESI model (specified in the section of characterization data).




2. Preparation of 1,1-difluoroalkenes by decarboxylation of sodium chlorodifluoroacetate.

The reactions were performed using a procedure similar to the ones described by Fuqua et al¹. A solution of a carbonyl compound (10 mmol) and triphenylphosphine (12 mmol, 3.15 g) in dry N-methylpyrrolidone (5 mL) was prepared in a Schlenk flask under Argon atmosphere. At 120 °C, solid ClCF₂CO₂Na (15 mmol, 2.29 g) was added portion wise over 30 min. After evolution of carbon dioxide ceased (c.a. 15 – 20 min after the addition of ClCF₂CO₂Na was complete), the reaction mixture was cooled down and transferred into a separation funnel containing diethyl ether (150 ml). The organic phase was washed with water (150 mL), 30% H₂O₂ (30 mL) and brine (3 x 100 mL), dried (Na₂SO₄) and evaporated. The product was purified by column chromatography on silica gel using hexanes or hexanes–AcOEt 50:1 as eluent.




4-(2,2-difluorovinyl)-1,1'-biphenyl(1a). 65% yield. **¹H NMR** (400 MHz, CDCl₃) δ 7.61–7.33 (m, 9H), 5.32 (dd, 1H, *J* = 3.8, 26.4 Hz); **¹³C NMR** (100 MHz, CDCl₃): δ 156.4 (dd, *J* = 288.0, 299.0 Hz), 140.5, 139.8(t, *J* = 2.0, 2.0 Hz), 129.4(t, *J* = 6.3, 6.3 Hz), 128.8, 128.0(dd, *J* = 3.6, 6.5 Hz), 127.4(2), 127.0, 82.0(dd, *J* = 13.4, 29.4 Hz). **¹⁹F NMR** (376 MHz, CDCl₃): δ -81.86 (dd, *J* = 26.7, 30.6 Hz, 1F), -83.80(dd, *J* = 3.6, 30.7 Hz, 1F); **¹⁹F {¹H} NMR** (376 MHz, CDCl₃): δ -81.83 (d, *J* = 30.6 Hz, 1F), -83.59(d, *J* = 30.6 Hz, 1F).




1-bromo-4-(2,2-difluorovinyl)benzene(1b). 73% yield. **¹H NMR** (400 MHz, CDCl₃) δ 7.45–7.17 (m, 4H), 5.22(dd, 1H, *J* = 3.6, 26.0 Hz); **¹³C NMR** (100 MHz, CDCl₃): δ 156.4 (dd, *J* = 289.7, 300.0 Hz), 131.8, 129.3(dd, *J* = 6.0, 7.2 Hz), 129.1(dd, *J* = 3.6, 6.6 Hz), 120.8(dd, *J* = 2.4, 3.2 Hz), 81.6(dd, *J* = 13.4, 29.7 Hz). **¹⁹F NMR** (376 MHz, CDCl₃): δ -81.20 (dd, *J* = 26.0, 29.0 Hz, 1F),

¹ S. A. Fuqua, W. G. Duncan and R. M. Silverstein, Organic Syntheses, 1967, 47, 19.


-83.04 (dd, $J = 3.6, 29.2$ Hz, 1F); ^{19}F { ^1H } **NMR** (376 MHz, CDCl_3): $\delta -81.20$ (d, $J = 29.6$ Hz, 1F), -83.59 (d, $J = 30.9$ Hz, 1F).




1-chloro-4-(2,2-difluorovinyl)benzene(1c). 55% yield. ^1H **NMR** (400 MHz, CDCl_3) $\delta 7.29\text{--}7.21$ (m, 4H), 5.21 (dd, 1H, $J = 3.6, 26.0$ Hz); ^{13}C **NMR** (100 MHz, CDCl_3): $\delta 156.4$ (dd, $J = 288.5, 298.5$ Hz), 132.8(t, $J = 2.7, 2.7$ Hz), 129.4(t, $J = 6.3, 6.3$ Hz), 128.9, 128.8(dd, $J = 3.6, 6.6$ Hz), 81.5(dd, $J = 13.8, 30.4$ Hz). ^{19}F **NMR** (376 MHz, CDCl_3): $\delta -81.53$ (dd, $J = 26.6, 30.0$ Hz, 1F), -83.84 (dd, $J = 3.3, 30.0$ Hz, 1F); ^{19}F { ^1H } **NMR** (376 MHz, CDCl_3): $\delta -81.51$ (d, $J = 30.0$ Hz, 1F), -83.34 (d, $J = 30.1$ Hz, 1F).



4-(2,2-difluorovinyl)-1,1'-biphenyl(1d). 65% yield. ^1H **NMR** (400 MHz, CDCl_3) $\delta 7.61\text{--}7.33$ (m, 9H), 5.32 (dd, 1H, $J = 3.8, 26.4$ Hz); ^{13}C **NMR** (100 MHz, CDCl_3): $\delta 156.4$ (dd, $J = 288.0, 299.0$ Hz), 140.5, 139.8(t, $J = 2.0, 2.0$ Hz), 129.4(t, $J = 6.3, 6.3$ Hz), 128.8, 128.0(dd, $J = 3.6, 6.5$ Hz), 127.4(2), 127.0, 82.0(dd, $J = 13.4, 29.4$ Hz). ^{19}F **NMR** (376 MHz, CDCl_3): $\delta -81.86$ (dd, $J = 26.7, 30.6$ Hz, 1F), -83.80 (dd, $J = 3.6, 30.7$ Hz, 1F); ^{19}F { ^1H } **NMR** (376 MHz, CDCl_3): $\delta -81.83$ (d, $J = 30.6$ Hz, 1F), -83.59 (d, $J = 30.6$ Hz, 1F).




1-(2,2-difluorovinyl)-4-methylbenzene(1e). 55% yield. ^1H **NMR** (400 MHz, CDCl_3) $\delta 7.22\text{--}7.12$ (m, 4H), 5.22 (dd, 1H, $J = 4.0, 28.0$ Hz), 2.33(s, 3H); ^{13}C **NMR** (100 MHz, CDCl_3): $\delta 156.1$ (dd, $J = 288.4, 298.4$ Hz), 136.8, 129.4, 127.5 (dd, $J = 3.6, 6.2$ Hz), 81.9 (dd, $J = 14.0, 29.0$ Hz), 21.1. ^{19}F **NMR** (376 MHz, CDCl_3): $\delta -83.22$ (dd, $J = 26.6, 34.0$ Hz, 1F), -85.32 (dd, $J = 3.4, 34.0$ Hz, 1F); ^{19}F { ^1H } **NMR** (376 MHz, CDCl_3): $\delta -83.20$ (d, $J = 34.0$ Hz, 1F), -85.32 (d, $J = 34.0$ Hz, 1F).




1-(2,2-difluorovinyl)-4-methylbenzene(1f). 43% yield. ^1H **NMR** (400 MHz, CDCl_3) $\delta 8.20\text{--}7.50$ (m, 4H), 5.40 (dd, 1H, $J = 3.1, 25.1$ Hz); ^{13}C **NMR** (100 MHz, CDCl_3): $\delta 156.9$ (dd, $J = 289.4, 298.3$ Hz), 148.6, 133.2(dd, $J = 3.6, 6.6$ Hz), 132.2(dd, $J = 6.2, 7.8$ Hz), 129.6, 122.3(dd, $J = 3.8, 6.9$ Hz), 121.8(t, $J = 1.8, 1.8$ Hz). ^{19}F **NMR** (376 MHz, CDCl_3): $\delta -79.03$ (dd, $J =$


24.6, 24.6 Hz, 1F), -80.74 (dd, J = 3.2, 24.1 Hz, 1F); ^{19}F { ^1H } NMR (376 MHz, CDCl_3): δ -79.01 (d, J = 24.0 Hz, 1F), -80.73(d, J = 24.1 Hz, 1F).



2-(2,2-difluorovinyl)naphthalene(1g). 61% yield. ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.76 (m, 4H), 7.50–7.47 (3H, m), 5.44(dd, 1H, J = 3.8, 26.3 Hz), ^{13}C NMR (100 MHz, CDCl_3) δ 156.4 (dd, J = 288.7, 298.6 Hz), 133.4, 132.3, 128.3, 127.8, 127.6, 126.6(dd, J = 4.8, 6.2 Hz), 126.4, 126.0, 125.4(dd, J = 2.5, 6.4 Hz), 82.5(dd, J = 13.3, 29.1 Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -81.88 (dd, J = 26.3, 30.9 Hz, 1F), -83.61(dd, J = 3.8, 30.9 Hz, 1F); ^{19}F { ^1H } NMR (376 MHz, CDCl_3): δ -81.85 (d, J = 30.9 Hz, 1F), -83.59(d, J = 30.9 Hz).




1,1-Difluoro-2-(1-naphthyl)ethane(1h). 73% yield. ^1H NMR (400 MHz, CDCl_3) δ , 7.86–7.37 (7H, m), 5.79 (dd, 1H, J = 3.0, 24.6 Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 156.8 (dd, J = 288.8, 296.5 Hz), 131.6, 131.5, 128.8, 128.1, 126.7, 126.6 (dd, J = 1.8, 6.5 Hz), 126.5, 126.1, 125.6, 123.8, 78.8 (dd, J = 15.4, 29.1 Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -82.99 (dd, J = 3.3, 29.5 Hz, 1F), -84.94(dd, J = 24.7, 29.1 Hz, 1F); ^{19}F { ^1H } NMR (376 MHz, CDCl_3): δ -82.98 (d, J = 29.3 Hz, 1F), -84.94(d, J = 28.8 Hz).




3. Synthesis of symmetric 3,6-dialkyl-1,2,4,5-tetrazine(3a–3h)

To a solution of 1,1-difluoroalkenes (**1a**, 50 mg, 0.27 mmol) in N,N-dimethylformide (DMF, 5 mL) was added hydrazine (80%, 35 mg, 1.35 mmol). After stirring at room temperature for 4–6 hours, saturated ammonium chloride (20 mL) was added and the reaction mixture was extracted with dichloromethane (10 mL×3). The organic layer was combined, dried with anhydrous sodium sulfate. The solvent was concentrated and the crude product was dissolved in a suspension of Ethyl Acetate(5 mL) and 10% potassium carbonate solution(wt%, 5 mL) and stirred at room temperature for 24h under air atomosphere until the organic layer turned into amaranth obviously. The organic layer was collected, dried with anhydrous sodium sulfate. The crude product was purified by flash column


chromatography[silica gel(#100–200), toluene] to afford the pure 1,2,4,5-tetrazines(**3a**–**3h**).




**3,6-bis([1,1'-biphenyl]-4-ylmethyl)-1,2,4,5-tetra
zine (**3a**)**. (41 mg, 83%). purple solid; **m.p.** 200–202°C; **IR(KBr)** $\text{n}_{\text{max}}/\text{cm}^{-1}$ 2924, 2850, 1488, 1451, 1432, 1388, 851, 750; **$^1\text{H NMR}$** (400 MHz, CDCl_3) 7.55–7.33 (m, 18H), 4.65 (s, 4H). **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 169.2, 140.6, 140.4, 134.8, 129.7, 128.8, 127.6, 127.4, 127.1, 40.9; **HRMS (ESI)**: calcd. for $\text{C}_{28}\text{H}_{22}\text{N}_4$ $[\text{M}+\text{H}]^+$ 415.19172, found 415.19124.



3,6-bis(4-bromobenzyl)-1,2,4,5-tetrazine (3b**)**. (124 mg, 77%). purple solid. **$^1\text{H NMR}$** (400 MHz, CDCl_3) 7.45–7.28 (m, 8H), 4.59 (s, 4H). **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 168.9, 134.6, 132.0, 131.0, 121.6, 40.6 {lit. **$^1\text{H NMR}$** (400 MHz, CDCl_3): δ 7.44 (d, $J = 8.4$, 4H), 7.29 (d, $J = 8.3$, 4H), 4.55 (s, 4H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3): δ 168.9 (u), 134.6 (u), 132.1 (dn), 131.0 (dn), 121.6 (u), 40.6 (u)}².



3,6-bis(4-chlorobenzyl)-1,2,4,5-tetrazine (3c**)**. (62 mg, 91%). purple solid. **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.38–7.30 (m, 8H), 4.59 (s, 4H). **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 169.0, 134.1, 133.5, 130.6, 129.1, 40.6. {lit.: **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ : 3.48 (s, 4H, CH₂), 6.13 (br, 2H, NH), 7.17–7.32 (m, 8H, Ph)}³.




**3,6-bis(4-(benzyloxy)benzyl)-1,2,4,5-tetr
azine (**3d**)**. (39 mg, 61%). purple solid. **m.p.** 164 °C; **IR(KBr)** $\text{n}_{\text{max}}/\text{cm}^{-1}$ 2926, 2905, 1614, 1513, 1470, 1454, 1432, 1383, 1298, 1178, 1013, 840, 697; **$^1\text{H NMR}$** (400 MHz, CDCl_3) 7.41–6.90 (m, 18H), 5.02 (s, 4H), 4.52 (s, 4H). **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 169.3, 158.1, 136.9, 130.4, 128.6, 128.2, 128.0, 127.4, 115.3, 70.0, 40.4;


² R. Selvaraj and J. M. Fox, *Tetrahedron Lett.*, 2014, 55, 4795–4797.

³ G. W. Rao and W. X. Hu, *Bioorg. Med. Chem. Lett.*, 2006, 16, 3702–3705.


HRMS (ESI): calcd. for $C_{30}H_{26}N_4O_2 [M+H]^+$ 475.21285, found 475.21242.




3,6-bis(4-methylbenzyl)-1,2,4,5-tetrazine (3e). m.p. 95–97 °C; (152 mg, 82%). purple solid. **1H NMR** (400 MHz, $CDCl_3$) 7.30–7.10 (m, 8H), 4.54 (s, 4H), 2.30 (s, 6H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 169.3, 137.0, 132.8, 129.3, 129.6, 129.1, 40.8, 21.0; **HRMS (ESI):** calcd. for $C_{18}H_{18}N_4 [M+H]^+$ 291.16042, found 291.16007. {lit¹ **1H NMR** (500 MHz, $CDCl_3$): δ =2.50 (s, 6H), 7.43 (d, J =8.0Hz, 4H), 8.54 (d, J =8.0Hz, 4H).}⁴



3,6-bis(3-nitrobenzyl)-1,2,4,5-tetrazine (3f). (26 mg, 66%). purple solid. **m.p.** 167–169°C; **IR(KBr)** $nmax/cm^{-1}$ 2922, 2851, 1525, 1470, 1381, 1346, 726; **1H NMR** (400 MHz, $CDCl_3$) 8.30–7.51 (m, 8H), 4.75 (s, 4H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 168.6, 148.6, 137.2, 135.5, 129.9, 124.4, 127.7, 40.4; **HRMS (ESI):** calcd. for $C_{16}H_{12}N_6O_4 [M+H]^+$, 355.11493, found 355.11458.




3,6-bis(naphthalen-2-ylmethyl)-1,2,4,5-tetrazine (3g). (101 mg, 61%). purple solid. **m.p.** 191–193 °C; **IR(KBr)** $nmax/cm^{-1}$ 2924, 2853, 1599, 1508, 1430, 1380, 836, 747; **1H NMR** (400 MHz, $CDCl_3$) 7.87–7.43 (m, 14H), 4.74 (s, 4H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 169.2, 133.5, 133.2, 132.5, 128.7, 128.1, 127.7, 127.7, 127.1, 126.3, 126.0, 41.4; **HRMS (ESI):** calcd. for $C_{24}H_{18}N_4 [M+H]^+$ 363.16024, found 363.15997.



3,6-bis(naphthalen-1-ylmethyl)-1,2,4,5-tetrazine (3h). (88 mg, 71%). purple solid. **m.p.** 151–153 °C; **IR(KBr)** $nmax/cm^{-1}$ 2924, 2853, 1596, 1511, 1397, 1377, 784, 766; **1H NMR** (400 MHz, $CDCl_3$)


⁴ H. X. Liu and Y. Y. Wei, *Tetrahedron Lett.*, 2013, 54, 4645–4648.

8.20–7.37 (m, 14H), 4.94 (s, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 169.2, 134.0, 132.2, 131.8, 128.8, 128.4, 128.4, 126.6, 125.9, 125.6, 124.0, 38.7; **HRMS (ESI)**: calcd. for C₂₄H₁₈N₄ [M+H]⁺ 363.16003, found 363.16042.




4. Synthesis of asymmetric 3,6-dialkyl-1,2,4,5-tetrazines (5a–5l)

In one flask, 1,1-difluoroalkenes (**1a** or **1c**, 0.11 mmol) and hydrazine (35 mg, 80%, 0.55 mmol) were stirred in DMF (3 mL) at room temperature. In another flask, another 1,1-difluoroalkene (1.1 mmol) and hydrazine (350 mg, 80%, 5.50 mmol) were stirred in DMF (3 mL) at room temperature. After 4–6 hours, the two reaction mixtures were mixed and saturated ammonium chloride (20 mL) was added. The reaction mixture was extracted with DCM (10mL×3). The solvent was evaporated and the crude product was dissolved in a suspension of Ethyl Acetate(5 mL) and 10% potassium carbonate solution(wt%, 5 mL) and then stirred at room temperature for 24h under air until the organic layer turned into amaranth obviously. Finally the organic layer was collected, dried with sodium sulfate and evaporated un vacuu. The crude product was purified by flash column chromatography [silica gel(#100–200), toluene] to afford the pure 1,2,4,5-tetrazines(**5a–5l**).




3-(4-(benzyloxy)benzyl)-6-(4-bromobenzyl)-1,2,4,5-tetrazine (5a). (29 mg, 85%). purple solid. **m.p.** 103–105 °C; **IR(KBr)** nmax/cm⁻¹ 2927, 2855, 1512, 1379, 1295, 1251, 787; **¹H NMR** (400 MHz, CDCl₃) 7.45–6.91 (m, 13H), 5.02(s, 2H), 4.54 (s, 4H); **¹³C NMR** (100 MHz, CDCl₃) δ 169.5, 168.7, 158.1, 136.9, 134.7, 132.0, 131.0, 130.4, 128.6, 128.0, 128.0, 127.4, 127.4, 121.5, 115.3, 70.0, 40.6, 40.4; **HRMS (ESI)**: calcd. for C₂₃H₁₉BrN₄O [M+H]⁺, 447.08150, found 447.08101.




3-(4-(benzyloxy)benzyl)-6-(4-chlorobenzyl)-1,2,4,5-tetrazine (5b). (26 mg, 84%). purple

solid. **m.p.** 98–100 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2924, 2852, 1514, 1492, 1382, 1253, 743; **¹H NMR** (400 MHz, CDCl_3) 7.39–6.91 (m, 13H), 5.02(s, 2H), 4.56 (s, 2H), 4.54(s, 2H); **¹³C NMR** (100 MHz, CDCl_3) δ 169.5, 168.8, 158.1, 136.9, 134.2, 133.4, 130.6, 130.4, 129.0, 128.6, 128.0, 127.4, 115.3, 70.0, 40.5, 40.4; **HRMS (ESI)**: calcd. for $\text{C}_{23}\text{H}_{19}\text{ClN}_4\text{O} [\text{M}+\text{H}]^+$, 403.13202, found 403.13133.




3-(4-(benzyloxy)benzyl)-6-(4-methylbenzyl)-1,2,4,5-tetrazine (5c). (35 mg, 87%) yield. purple solid. **m.p.** 94–96 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2922, 2854, 1529, 1383, 1248,

1012, 740; **¹H NMR** (400 MHz, CDCl_3) 7.38–6.90 (m, 13H), 5.02(s, 2H), 4.54(s, 2H), 4.52(s, 2H), 2.30(s, 3H); **¹³C NMR** (100 MHz, CDCl_3) δ 169.3, 169.3, 158.1, 137.0, 136.9, 132.8, 130.3, 129.5, 129.1, 128.6, 128.2, 127.9, 127.4, 115.3, 70.0, 40.8, 40.4, 21.0; **HRMS (ESI)**: calcd. for $\text{C}_{24}\text{H}_{22}\text{N}_4\text{O} [\text{M}+\text{H}]^+$, 383.18664, found 383.18637.




3-([1,1'-biphenyl]-4-ylmethyl)-6-(4-(benzyloxy)benzyl)-1,2,4,5-tetrazine (5d). (17 mg, 79%). purple solid. **m.p.** 131–133 °C;

IR(KBr) $\text{nmax}/\text{cm}^{-1}$ 2925, 2853, 1514, 1383, 1245, 1013, 755; **¹H NMR** (400 MHz, CDCl_3) 7.55–6.90 (m, 18H), 5.02 (s, 2H), 4.63(s, 2H), 4.54(s, 2H); **¹³C NMR** (100 MHz, CDCl_3) δ 169.4, 169.1, 130.4, 129.7, 128.8, 128.6, 128.0, 127.6, 127.4, 127.4, 127.1, 115.3, 70.1, 40.9, 40.4; **HRMS (ESI)**: calcd. for $\text{C}_{29}\text{H}_{24}\text{N}_4\text{O} [\text{M}+\text{H}]^+$, 445.20229, found 445.20164.




3-([1,1'-biphenyl]-4-ylmethyl)-6-(4-(benzyloxy)benzyl)-1,2,4,5-tetrazine (5e). (124 mg, 83%). purple solid. **m.p.** 146–148 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2921, 2849, 1513, 1383, 1248, 1014, 836; **¹H NMR** (400 MHz, CDCl_3) 7.86–6.89 (m, 17H), 5.01 (s, 2H), 4.75(s, 2H), 4.53(s, 2H); **¹³C NMR** (100 MHz, CDCl_3) δ 169.4, 169.1, 158.5, 136.9, 133.3, 132.5, 130.3, 128.6, 128.6, 128.1, 128.0, 127.7,

127.7, 127.4, 127.1, 126.3, 126.0, 115.3, 70.0, 41.4, 40.4; **HRMS (ESI)**: calcd. for $C_{27}H_{22}N_4O$ $[M+H]^+$, 419.18644, found 419.18634.




3-(4-(benzyloxy)benzyl)-6-(naphthalen-1-ylmethyl)-1,2,4,5-tetrazine (5f). (18 mg, 80%). purple solid. **m.p.** 106-108 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2923, 2855, 1513,


1415, 1377, 1245, 1046, 786; **¹H NMR** (400 MHz, CDCl₃) 8.27–8.24 (m, 1H), 7.38–7.25 (m, 14H); 6.90–6.88 (d, *J* = 8Hz, 2H); 5.03 (s, 2H), 5.00(s, 2H), 4.49(s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 169.3, 169.2, 158.1, 136.9, 134.0, 132.2, 130.4., 128.8, 128.6, 128.4, 128.1, 128.0, 127.4, 126.6, 125.9, 125.6, 124.0, 70.0, 40.4, 38.7; **HRMS (ESI)**: calcd. for $C_{27}H_{22}N_4O$ $[M+H]^+$, 419.18644, found 419.18634.




3-(4-bromobenzyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5g). (13 mg, 77%). purple solid. **m.p.** 80-82 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2920, 2849, 1529, 1491, 1380, 1351 733; **¹H NMR** (400 MHz, CDCl₃) 8.29–7.29 (m, 8H), 4.72 (s, 2H), 4.58(s, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 169.2, 168.4, 148.5, 137.4, 135.5, 134.4, 132.1, 131.0, 129.9, 122.6, 121.7, 40.7, 40.7; **HRMS (ESI)**: calcd. for $C_{16}H_{12}BrN_5O_2$ $[M+H]^+$, 386.02471, found 386.02430.




3-(4-chlorobenzyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5h). (31 mg, 76%). purple solid. **m.p.** 75-77 °C; **IR(KBr)** $\text{nmax}/\text{cm}^{-1}$ 2920, 2849, 1529, 1491, 1380, 1351,733; **¹H NMR** (400 MHz, CDCl₃) 8.30–7.28 (m, 8H), 4.72 (s, 2H), 4.59(s, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 169.2, 168.4, 137.4, 135.5, 133.9, 133.6, 130.6, 129.9, 129.1, 124.4, 122.6, 40.7, 40.6; **HRMS (ESI)**: calcd. for $C_{16}H_{12}ClN_5O_2$ $[M+H]^+$, 342.07523, found 342.07474.




3-(4-methylbenzyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5i). (22 mg, 81%). purple solid. **m.p.** 73-75 °C; **IR(KBr)** nmax/cm⁻¹ 2922, 2851, 1522, 1426, 1382, 1345, 730; **¹H NMR** (400 MHz, CDCl₃) 8.30–7.28 (m, 8H), 4.72 (s, 2H), 4.59(s, 2H), 2.17(s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 169.2, 168.4, 148.5, 137.4, 135.5, 133.9, 130.6, 129.9, 129.1, 124.4, 122.6, 40.9, 40.7, 21.0; **HRMS (ESI)**: calcd. for C₁₇H₁₅N₅O₂ [M+H]⁺, 322.12985, found 322.12946.



3-([1,1'-biphenyl]-4-ylmethyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5j). (24 mg, 78%). purple solid. **m.p.** 92-94°C; **IR(KBr)** nmax/cm⁻¹ 2925, 2853, 1529, 1488, 1380, 1350, 759; **¹H NMR** (400 MHz, CDCl₃) 8.31–7.26 (m, 13H), 5.02(s, 2H), 4.72(s, 2H), 4.67(s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 169.6, 168.3, 140.5, 137.5, 135.5, 134.5, 129.7, 128.8, 127.7, 127.4, 127.0, 124.4, 122.6, 40.9, 40.7; **HRMS (ESI)**: calcd. for C₂₂H₁₇N₅O₂ [M+H]⁺, 384.14550, found 384.14503.




3-(naphthalen-2-ylmethyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5k). (19 mg, 83%). purple solid. **m.p.** 113-115 °C; **IR(KBr)** nmax/cm⁻¹ 2922, 2851, 1529, 1464, 1380, 1353, 734; **¹H NMR** (400 MHz, CDCl₃) 8.29–7.44 (m, 13H), 4.78(s, 2H), 4.70(s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 168.6, 167.3, 146.1, 134.5, 132.5, 131.9, 131.5, 128.8, 127.9, 127.7, 127.1, 126.7, 126.6, 126.0, 125.4, 125.1, 123.4, 121.6, 40.4, 39.7; **HRMS (ESI)**: calcd. for C₂₀H₁₅N₅O₂ [M+H]⁺, 358.12985, found 358.12924.



3-(naphthalen-1-ylmethyl)-6-(3-nitrobenzyl)-1,2,4,5-tetrazine (5l). (18 mg, 78%). **m.p.** 100-102 °C; **IR(KBr)** nmax/cm⁻¹ 2922, 2850, 1529, 1463, 1379, 1351, 790; **¹H NMR** (400 MHz, CDCl₃) purple solid. 8.28–7.48 (m, 11H), 5.07 (s, 2H), 4.68(s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 169.8, 168.0, 137.4, 135.5, 134.0, 131.9,

131.7, 129.8, 128.9, 128.5, 128.4, 126.7, 126.0, 125.7, 124.4, 123.8, 122.6, 40.7, 38.8; **HRMS (ESI):**
calcd. for $C_{20}H_{15}N_5O_2 [M+H]^+$, 358.12985, found 358.12971.

5. Screen of the solvent effect in the conversion of gem-difluoroalkene **1a to fluorohydrazone **2a**^a**




Solvent	Temperature (° C)	Conversion (%)
Toluene	RT	3
CH ₂ Cl ₂	RT	0
CHCl ₃	RT	0
THF	RT	52
THF	40	61
THF	60	65
THF	80	67
DMF	RT	99


^aThe conversion was calculated based on the recovery of the starting material.

6. NMR spectra of novel compounds and intermediate


¹H NMR (CDCl₃, 400 MHz, 25 °C) of **3a**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **3a**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **3b**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **3b**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **3c**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **3c**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **3d**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **3d**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **3e**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **3e**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **3f**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **3f**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **3g**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **3g**





¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **3h**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **3h**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5a**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **5b**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **5b**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5c**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5c**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5d**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5d**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5e**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5e**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **5f**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **5f**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **5g**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **5g**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5h**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5h**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **5i**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **5i**




¹H NMR (CDCl₃, 400 MHz, 25 °C) of **5j**




¹³C NMR (CDCl₃, 100 MHz, 25 °C) of **5j**




¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5k**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5k**



¹H NMR (CDCl_3 , 400 MHz, 25 °C) of **5l**




¹³C NMR (CDCl_3 , 100 MHz, 25 °C) of **5l**



7. NMR comparison of 1a and fluorohydrazone 2a in CD₃CN

¹⁹FNMR (CD₃CN, 376MHz, 25 °C)



¹H NMR (CD₃CN, 400MHz, 25 °C)

